Patient demographics and baseline characteristics
| Characteristic . | Liso-cel–treated analysis set (n = 61) . |
|---|---|
| Age, y | |
| Median (range) | 74 (53-84) |
| <70, n (%) | 13 (21) |
| 70-74, n (%) | 20 (33) |
| ≥75, n (%) | 28 (46) |
| Male sex, n (%) | 37 (61) |
| Race, n (%) | |
| White | 54 (89) |
| Other | 3 (5) |
| Missing | 4 (7) |
| Histology, n (%) | |
| DLBCL NOS | 33 (54) |
| Transformed FL | 9 (15) |
| HGBCL | 18 (30) |
| FL3B | 1 (2) |
| Double or triple hit, n (%) | |
| Yes | 20 (33) |
| No | 37 (61) |
| Missing | 4 (7) |
| R/R, n (%) | |
| Relapsed | 28 (46) |
| Relapsed ≤12 months | 13 (21) |
| Relapsed >12 months | 15 (25) |
| Refractory∗ | 33 (54) |
| Bone marrow involvement, n (%) | 7 (11) |
| LVEF of <50%, n (%) | 1 (2) |
| CrCl of <60 mL/min, n (%) | 15 (25) |
| AST/ALT of >2 × ULN, n (%) | 0 |
| Screening ECOG PS, n (%) | |
| 0/1/2 | 19 (31)/26 (43)/16 (26) |
| Screening aaIPI, n (%) | |
| 0-1/2-3 | 34 (56)/26 (43) |
| Missing | 1 (2) |
| Pre-LDC LDH of ≥500 U/L, n (%) | 11 (18) |
| Pre-LDC SPD per IRC of ≥50 cm2, n (%) | 10 (16) |
| Median baseline CRP (range), mg/L | 14 (0.5-617) |
| Screening HCT-CI score, n (%) | |
| 0-2/≥3 | 34 (56)/27 (44) |
| Best previous response to any previous therapies after diagnosis, n (%) | |
| CR | 28 (46) |
| PR | 15 (25) |
| SD | 5 (8) |
| PD | 13 (21) |
| Received bridging therapy,† n (%) | 32 (52) |
| Months from diagnosis to first liso-cel infusion, median (range) | 14 (2-183) |
| Characteristic . | Liso-cel–treated analysis set (n = 61) . |
|---|---|
| Age, y | |
| Median (range) | 74 (53-84) |
| <70, n (%) | 13 (21) |
| 70-74, n (%) | 20 (33) |
| ≥75, n (%) | 28 (46) |
| Male sex, n (%) | 37 (61) |
| Race, n (%) | |
| White | 54 (89) |
| Other | 3 (5) |
| Missing | 4 (7) |
| Histology, n (%) | |
| DLBCL NOS | 33 (54) |
| Transformed FL | 9 (15) |
| HGBCL | 18 (30) |
| FL3B | 1 (2) |
| Double or triple hit, n (%) | |
| Yes | 20 (33) |
| No | 37 (61) |
| Missing | 4 (7) |
| R/R, n (%) | |
| Relapsed | 28 (46) |
| Relapsed ≤12 months | 13 (21) |
| Relapsed >12 months | 15 (25) |
| Refractory∗ | 33 (54) |
| Bone marrow involvement, n (%) | 7 (11) |
| LVEF of <50%, n (%) | 1 (2) |
| CrCl of <60 mL/min, n (%) | 15 (25) |
| AST/ALT of >2 × ULN, n (%) | 0 |
| Screening ECOG PS, n (%) | |
| 0/1/2 | 19 (31)/26 (43)/16 (26) |
| Screening aaIPI, n (%) | |
| 0-1/2-3 | 34 (56)/26 (43) |
| Missing | 1 (2) |
| Pre-LDC LDH of ≥500 U/L, n (%) | 11 (18) |
| Pre-LDC SPD per IRC of ≥50 cm2, n (%) | 10 (16) |
| Median baseline CRP (range), mg/L | 14 (0.5-617) |
| Screening HCT-CI score, n (%) | |
| 0-2/≥3 | 34 (56)/27 (44) |
| Best previous response to any previous therapies after diagnosis, n (%) | |
| CR | 28 (46) |
| PR | 15 (25) |
| SD | 5 (8) |
| PD | 13 (21) |
| Received bridging therapy,† n (%) | 32 (52) |
| Months from diagnosis to first liso-cel infusion, median (range) | 14 (2-183) |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; CrCl, creatinine clearance; CRP, C-reactive protein; FL3B, FL grade 3B; HCT-CI, hematopoietic cell transplant–specific comorbidity index; HGBCL, high-grade B-cell lymphoma; LDH, lactate dehydrogenase; LVEF, left ventricular ejection fraction; NOS, not otherwise specified; PD, progressive disease; PR, partial response; SD, stable disease; SPD, sum of the product of perpendicular diameters; ULN, upper limit of normal.
Defined as less than a CR to first-line therapy.
Defined as any systemic treatment or radiotherapy provided to patients for disease control after consent and before LDC (1 patient received radiotherapy only).